

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Previously presented) A mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprising the substitution of a neutral and/or hydrophobic amino acid for one or more of the following:

- (a) Glutamate 89; or
- (b) Aspartate 101; or
- (c) Leucine 137.

2. (Original) The mutein of claim 1 which comprises the substitution of a hydrophobic amino acid for Glu<sup>89</sup>.

3. (Original) The mutein of claim 1 which comprises the substitution of a hydrophobic amino acid for Asp<sup>101</sup>.

4. (Original) The mutein of claim 1 which comprises the substitution of a hydrophobic amino acid for Leu<sup>137</sup>.

5. (Original) The mutein of claim 1 which comprises the substitution of a neutral amino acid for Glu<sup>89</sup>.

6. (Original) The mutein of claim 1 which comprises the substitution of a neutral amino acid for Asp<sup>101</sup>.

7. (Original) The mutein of claim 1 which comprises the substitution of a neutral amino acid for Leu<sup>137</sup>.

8. (Original) The mutein of claim 1 wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

9-16 (Cancelled).

17. (Original) The mutein of claim 1 which is human basic fibroblast growth factor [Tyr<sup>101</sup>].

18. (Original) The mutein of claim 1 which is human basic fibroblast growth factor [Tyr<sup>137</sup>].
19. (Original) The mutein of claim 1 which is human basic fibroblast growth factor [Tyr<sup>89, 101</sup>].
20. (Original) The mutein of claim 1 which is human basic fibroblast growth factor [Tyr<sup>89, 137</sup>].
21. (Original) The mutein of claim 1 which is human basic fibroblast growth factor [Tyr<sup>101, 137</sup>].
22. (Original) The mutein of claim 1 which is human basic fibroblast growth factor [Tyr<sup>89, 101 137</sup>].
23. (Previously presented) A polynucleotide encoding the mutein of claim 1.
24. (Original) The polynucleotide of claim 23 which is DNA.
25. (Original) The polynucleotide of claim 23 which is genomic DNA.
26. (Original) The polynucleotide of claim 23 which is a cDNA.
27. (Original) The polynucleotide-of claim 23 which is RNA.
28. (Original) A vector containing the DNA of claim 25.
29. (Original) A vector containing the DNA of claim 26.
30. (Original) A vector containing the RNA of claim 27.
31. (Original) A host cell comprising the vector of claim 28.
32. (Original) A host cell comprising the vector of claim 29.
33. (Original) A host cell comprising the vector of claim 30.

34. (Original) A process for producing a polypeptide comprising expressing from the host cell of claim 32 the polypeptide encoded by said DNA.

35. (Original) A process for producing a polypeptide comprising expressing from the host cell of claim 33 the polypeptide encoded by said DNA.

36. (Original) A process for producing the vector of claim 28 which comprises:

- (a) inserting the polynucleotide of claim 25 into the vector; and
- (b) selecting and propagating said vector in a host cell.

37. (Original) A process for producing the vector of claim 29 which comprises:

- (a) inserting the polynucleotide of claim 26 into the vector; and
- (b) selecting and propagating said vector in a host cell.

38. (Original) A process for producing the vector of claim 30 which comprises:

- (a) creating a recombinant RN A molecule containing the RN A sequence of claim 27; and
- (b) selecting and propagating said vector in a host cell.

39. (Cancelled)

40. (Original) A pharmacologic composition useful for stimulating cell division comprising the following:

- (a) An effective amount of the human basic fibroblast growth factor mutein of claim 1; and
- (b) An acceptable pharmaceutical carrier.

41-47 (Cancelled)

48. (Currently amended) The mutein of claim 1, wherein said neutral amino acid is selected from the group consisting of serine, threonine, alanine, asparagine, glutamine, cysteine, glycine and histidine ~~and serine~~, and said hydrophobic amino acid is selected from the group consisting of tyrosine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.

**DOCKET NO.:** 3DP-0455  
**Application No.:** 09/722,495  
**Office Action Dated:** November 5, 2002

**PATENT**  
**REPLY FILED UNDER EXPEDITED**  
**PROCEDURE PURSUANT TO**  
**37 CFR § 1.116**

49. (Previously presented) The polynucleotide of claim 23, wherein said neutral amino acid is selected from the group consisting of serine, threonine, alanine, asparagine, glutamine, cysteine, glycine and histidine ~~and serine~~, and said hydrophobic amino acid is selected from the group consisting of tyrosine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.

50-67 (Cancelled)